Samyang Biopharmaceuticals Corporation
Clinical trials sponsored by Samyang Biopharmaceuticals Corporation, explained in plain language.
-
New device aims to smooth away smile lines in quick trial
Symptom relief Recruiting nowThis study tests a device called DMFI150 to see if it safely reduces nasolabial folds (smile lines). 30 adults aged 18-70 with moderate to severe wrinkles will receive a single treatment. Doctors will rate wrinkle changes over 12 months using a standard scale.
Phase: NA • Sponsor: Samyang Biopharmaceuticals Corporation • Aim: Symptom relief
Last updated May 26, 2026 12:12 UTC
-
New filler aims to smooth smile lines in Head-to-Head trial
Symptom relief Recruiting nowThis study tests a new injectable filler called DMFI300 for nasolabial folds (smile lines). 30 adults will receive both DMFI300 and a comparator filler on opposite sides of their face to compare how well each reduces wrinkles and their safety over 12 months.
Phase: NA • Sponsor: Samyang Biopharmaceuticals Corporation • Aim: Symptom relief
Last updated May 26, 2026 12:11 UTC